tiprankstipranks
Advertisement
Advertisement

VNDA Stock Latest News

Vanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan
The FlyVanda Pharmaceuticals’ imsidolimab granted orphan drug designation in Japan
6d ago
VNDA
Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
PremiumThe Fly
Vanda Pharmaceuticals price target lowered to $21 from $24 at H.C. Wainwright
22d ago
VNDA
Vanda Pharmaceuticals Bets Big on Growth Pipeline
PremiumCompany Announcements
Vanda Pharmaceuticals Bets Big on Growth Pipeline
26d ago
VNDA
Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
PremiumThe Fly
Vanda Pharmaceuticals reports Q1 EPS (82c) vs. (50c) last year
27d ago
VNDA
Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
PremiumThe Fly
Vanda Pharmaceuticals raises FY26 revenue view to $240M-$290M from $230-$260M
27d ago
VNDA
Vanda Pharmaceuticals announces U.S. commercial availability of Nereus
PremiumThe FlyVanda Pharmaceuticals announces U.S. commercial availability of Nereus
29d ago
VNDA
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
Premium
The Fly
AnaptysBio price target lowered to $93 from $95 at Piper Sandler
29d ago
GSK
ANAB
VNDA Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
VNDA Earnings this Week: How Will it Perform?
29d ago
VNDA
Vanda Pharmaceuticals announces commercial availability for Nereus
PremiumThe Fly
Vanda Pharmaceuticals announces commercial availability for Nereus
1M ago
VNDA
Vanda Pharmaceuticals Adds Independent Director to Strengthen Board
PremiumCompany Announcements
Vanda Pharmaceuticals Adds Independent Director to Strengthen Board
1M ago
8K
VNDA
AnaptysBio price target lowered to $60 from $90 at UBS
PremiumThe Fly
AnaptysBio price target lowered to $60 from $90 at UBS
1M ago
GSK
ANAB
Geron appoints Timothy Williams as chief legal officer
PremiumThe Fly
Geron appoints Timothy Williams as chief legal officer
2M ago
GERN
VNDA
Vanda calls on FDA to remove proposal extending drug review timelines
PremiumThe FlyVanda calls on FDA to remove proposal extending drug review timelines
2M ago
VNDA
Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial
Premium
Ratings
Vanda Pharmaceuticals: Undervalued GLP-1 Adjunct Opportunity Driven by Tradipitant’s Pivotal Thetis Trial
2M ago
VNDA
Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting
Premium
The Fly
Vanda Pharmaceuticals initiates trial of tradipitant in GLP-1-caused vomiting
2M ago
VNDA
Vanda Announces Resignation of Senior Legal Executive
PremiumCompany Announcements
Vanda Announces Resignation of Senior Legal Executive
2M ago
8K
VNDA
Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy
PremiumCompany Announcements
Vanda Advances NEREUS Launch With Direct-to-Consumer Strategy
3M ago
8K
VNDA
Vanda Pharmaceuticals initiated with a Buy at Truist
PremiumThe Fly
Vanda Pharmaceuticals initiated with a Buy at Truist
3M ago
VNDA
AnaptysBio provides update on potential spin-off of biopharma operations
PremiumThe Fly
AnaptysBio provides update on potential spin-off of biopharma operations
3M ago
GSK
ANAB
Vanda Pharmaceuticals: FDA grants hearing to review sNDA for Hetlioz
PremiumThe FlyVanda Pharmaceuticals: FDA grants hearing to review sNDA for Hetlioz
3M ago
VNDA
Vanda Pharmaceuticals: Limited Downside, Pipeline-Driven Upside Supports $24 Target Price
Premium
Ratings
Vanda Pharmaceuticals: Limited Downside, Pipeline-Driven Upside Supports $24 Target Price
3M ago
VNDA
Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley
Premium
The Fly
Vanda Pharmaceuticals price target raised to $17 from $14 at B. Riley
3M ago
VNDA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >